scholarly journals Bilateral Basal Ganglion Hemorrhage after Severe Olanzapine Intoxication

2020 ◽  
Vol 2020 ◽  
pp. 1-3 ◽  
Author(s):  
Kerstin Schweyer ◽  
Bastian Fatke ◽  
Kornelia Kreiser ◽  
Christian Rabe ◽  
Christian Seifert ◽  
...  
Keyword(s):  
Intracerebral Hemorrhage ◽  
Arterial Hypertension ◽  
Basal Ganglion ◽  
Intracranial Hemorrhage ◽  
Vascular Malformation ◽  
Side Effect ◽  
Clinical Relevance ◽  
High Dose ◽  
Prescription Rates ◽  
Second Generation Antipsychotic

Olanzapine is a second-generation antipsychotic drug which is generally considered safe with well therapeutic antipsychotic effects. We describe a patient suffering from bilateral intracerebral hemorrhage after severe olanzapine intoxication without underlying thrombocytopenia, arterial hypertension, or vascular malformation as cause of intracerebral hemorrhage. This raises the possibility of a direct side effect of high-dose olanzapine intake. So far, intracranial hemorrhage after olanzapine intoxication in such constellation has not been reported before. Given the high number of its prescription rates, our finding of intracranial hemorrhage after olanzapine intoxication is of high clinical relevance.

757: HIGH-DOSE FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE FOR WARFARIN-INDUCED INTRACEREBRAL HEMORRHAGE

2016 ◽  
Vol 44 (12) ◽  
pp. 265-265
Author(s):  
Cristian Merchan ◽  
Veronica Raco ◽  
Tania Ahuja ◽  
Ariane Lewis
Keyword(s):  
Intracerebral Hemorrhage ◽  
Prothrombin Complex Concentrate ◽  
High Dose

scholarly journals High Dose Deferoxamine in Intracerebral Hemorrhage (Hi-Def) Trial: Rationale, Design, and Methods

2013 ◽  
Vol 19 (2) ◽  
pp. 257-266 ◽  
Author(s):  
Sharon D. Yeatts ◽  
Yuko Y. Palesch ◽  
Claudia S. Moy ◽  
Magdy Selim
Keyword(s):  
Intracerebral Hemorrhage ◽  
High Dose ◽  
Design And Methods

High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage

2021 ◽  
Author(s):  
Spencer Davis ◽  
Stephanie Chauv ◽  
Abby W. Hickman ◽  
Dave S. Collingridge ◽  
Sara Kjerengtroen ◽  
...  
Keyword(s):  
Intracranial Hemorrhage ◽  
Prothrombin Complex Concentrate ◽  
Low Dose ◽  
Factor Xa ◽  
High Dose ◽  
Factor Xa Inhibitor

scholarly journals Case Report: Factor VII Deficiency Presented With Cephalohematoma After Birth

2021 ◽  
Vol 9 ◽  
Author(s):  
Yuan-Chun Lo ◽  
Ching-Tien Peng ◽  
Yin-Ting Chen
Keyword(s):  
Replacement Therapy ◽  
Intracranial Hemorrhage ◽  
Hypovolemic Shock ◽  
Rehabilitation Program ◽  
Factor Vii ◽  
High Dose ◽  
Homozygous Mutation ◽  
Recombinant Activated Factor Vii ◽  
Factor Vii Deficiency ◽  
Activated Factor Vii

Introduction: Factor VII deficiency is a rare inherited autosomal recessive bleeding disorder with a global prevalence of 1/500,000. Most cases remain asymptomatic, and cases with severe clinical presentation are rarely reported.Case Presentation: A newborn male with no relevant maternal antenatal history, delivered via vacuum-assisted cesarean section, presented with a large cephalohematoma after delivery. Poor appetite, pale appearance, and bulging fontanelles were observed 2 days later, progressing to hypovolemic shock. Further imaging examination revealed a large intracranial hemorrhage. Serial laboratory examination revealed remarkable coagulopathy with prolonged prothrombin time and factor VII deficiency (<1%, severe type). The patient was genetically confirmed to have the FVII:c 681+1 G>T homozygous mutation. Brain hemorrhage was resolved with high-dose factor VII replacement therapy with recombinant activated factor VII. However, repeated hemothorax and intracranial hemorrhage were detected. Therefore, the patient was under regular factor VII supplementation with a rehabilitation program for cerebral palsy.Conclusions: A case of factor VII deficiency with large cephalohematoma and intracranial hemorrhage after birth is described herein, which was treated with high-dose replacement therapy. Variants of the FVII:c 681+1 G>T (IVS6+1G>T) homozygous genotype may present with a severe phenotype at the neonatal stage. We aim to share a unique neonatal presentation with a certain genotype and treatment experience with initial replacement therapy, followed by regular prophylactic dosage.

An Open Study of Two Dose Levels of ‘Vivalan’ (Viloxazine Hydrochloride ICI 58 834) in Depression in General Practice

1974 ◽  
Vol 2 (4) ◽  
pp. 253-259 ◽  
Author(s):  
P F C Bayliss ◽  
J W Harcup ◽  
M Mayer ◽  
R Million ◽  
J E Murphy ◽  
...  
Keyword(s):  
General Practice ◽  
Depressive Symptoms ◽  
Side Effects ◽  
Side Effect ◽  
Open Study ◽  
Anxiety Symptoms ◽  
High Dose ◽  
Dose Levels

Forty-eight mild to moderate depressives were treated by six genera practitioners with a chemically novel anti-depressant, ‘Vivalan’ (viloxazine hydrochloride, ICI 58 834). Twenty-five patients took 150 mg/day in three divided doses, and twenty-three took 200 mg/day in two divided doses, each for twenty-one days. The severity of both the depressive symptoms and the anxiety symptoms showed a statistically highly significant reduction over the duration of the study. There was no difference between the efficacy of the two dose levels. Viloxazine was generally well tolerated and there was no difference between the two dose levels as far as side-effects or withdrawals were concerned. The usual sedative and anti-cholinergic side-effects of the tricyclic anti-depressants were virtually absent. The only side-effect seen was a transient upper gastro-intestinal disturbance. It was commoner at the high dose but not significantly so. It is concluded that viloxazine hydrochloride appears to be an effective anti-depressant in this type of patient and produces little or no sedative or anti-cholinergic side-effects. Either 150 mg/day or 200 mg/day would seem a reasonable dose to use in general practice.

Abstract WMP35: The Characteristics of Infectious Intracranial Aneurysm and Indication of Cerebral Angiogram in Infective Endocarditis (IE)

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Sung-Min Cho ◽  
Robert Marquardt ◽  
Lucy Zhang ◽  
Prateek Thatikunta ◽  
Ken Uchino ◽  
...  
Keyword(s):  
Infective Endocarditis ◽  
Intracranial Aneurysm ◽  
Intracerebral Hemorrhage ◽  
Intracranial Hemorrhage ◽  
Cerebral Angiogram ◽  
Tertiary Referral Center ◽  
Valvular Surgery ◽  
Imaging Characteristics ◽  
Perioperative Complication ◽  
Glue Embolization

Introduction: Infectious intracranial aneurysm (IIA) can complicate infective endocarditis (IE). We aim to describe the characteristics of IIA and to assess indications for cerebral angiography. Methods: We reviewed IIAs among 116 consecutive active IE by Duke’s criteria with neurological consultation or admission to stroke neurology service in a single tertiary referral center from January 2015 to July 2016. Susceptibility weighted imaging (SWI) hemorrhage was defined as low signal on SWI in sulci or parenchyma that was not apparent on CT. Results: Of 116 patients, 74 persons (63.8%, mean age of 54) underwent digital subtraction angiography (DSA). IIAs were identified in 13 (17.6%). All of 13 IIAs were unruptured and only one IIA had unrelated intracranial hemorrhage on CT. None of the IIA was seen with CTA or MRA. Eleven (85%) IIAs had clinical strokes (10 ischemic strokes, 1 intracerebral hemorrhage, median NIH stroke scale 3), and 2 neurologically asymptomatic with abnormal MRI. Six of 9 IIAs had SWI hemorrhage in sulci or parenchyma (5 in sulci, 5 in parenchyma, and 1 in both) and all of the lesions were in the vicinity of IIA. Contrast MRI was performed in 7 IIAs, and 4 IIAs had enhancements, all of which were present near the location of IIAs. Ischemic stroke, intracranial hemorrhage, intravenous drug abuse, and type of valve were not associated with the presence of IIA. Of 13 IIAs, 3 remained on antibiotic alone, 5 had antibiotic with coil embolization, and, 5 had antibiotic with glue embolization. Ten patients with IIAs had valvular surgery, including one person with untreated IIA. Out of all patients with IIA, only one intracerebral hemorrhage occurred as perioperative complication unrelated to treated IIA. Conclusions: IIAs were found in approximately one fifth of IE persons who underwent DSA. Imaging characteristics such as SWI hemorrhage in sulci or parenchyma and contrast enhancement appear to correlate with the presence of IIA. DSA should be performed when they are present.

scholarly journals Clinical and Head Ultrasound Findings in Neonates after Administration of High Dose of Vitamin A

2018 ◽  
Vol 34 (7-8) ◽  
pp. 197-208
Author(s):  
R M Nurrachim ◽  
Ali Usman ◽  
Sjarif Hidajat ◽  
Dedi Subardja ◽  
Tina Agoestina ◽  
...  
Keyword(s):  
Vitamin A ◽  
Intracranial Hemorrhage ◽  
Vitamin A Deficiency ◽  
Resistive Index ◽  
Control Group ◽  
High Dose ◽  
Study Group ◽  
Intracranial Volume ◽  
Cranial Ultrasound ◽  
Ultrasound Findings

Vitamin A deficiency is a major cause of blindness and severe morbidity and mortality in young children. Supplementation of vitamin A in the community might reduce child mortality rates. The safety of high dose of vitamin A administered to neonates is not clear. We randomized 2058 neonates to receive either a single dose of 50 000 IU oral vitamin A (n=l031) or placebo (n=l027). Bulging fontanel and head circumference were assessed before and throughout 48 hours following dosing. Cranial ultrasound examination was carried out in 972 infants before and 24 hours after dosing to rule out intracranial hemorrhage and determine resistive index (Rl) of the anterior cerebral artery. Slight bulging fontanel occurred in 2. 7% and 4.4% of the infants at 24 hours. Moderate bulging fontanel was seen in 0.1% of study group, no severe bulging was observed. At 48 hours slight bulging fontanel was observed in 2.4% of control group and 4.5% in study group. No intracranial hemorrhage was found. Mean RI values were normal in both groups at baseline or 24 hours. Bulging fontanel was not associated with increased signs or symptom, or with increase in RI. Single oral dose of 50 000 vitamin A may cause a small increase in intracranial volume in a small proportion of infants, without increase in intracranial pressure.

Sign in / Sign up

Export Citation Format

Share Document